PHASE 3 RANDOMIZED TRIAL OF MOMELOTINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH MYELOFIBROSIS PREVIOUSLY TREATED WITH RUXOLITINIB: RESULTS OF THE SIMPLIFY-2 STUDY

被引：0
|
作者：
Verstovsek, S. [1 ]
Vannucchi, A. M. [2 ]
Platzbecker, U. [3 ]
Cervantes, F. [4 ]
Gupta, V. [5 ]
Lavie, D. [6 ]
Passamonti, F. [7 ]
Winton, E. F. [8 ]
Dong, H. [9 ]
Kawashima, J. [9 ]
Maltzman, J. D. [9 ]
Kiladjian, J-J. [10 ,11 ]
Harrison, C. N. [12 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Florence, Florence, Italy
[3] Tech Univ, Med Fak Carl Gustav Carus, Dresden, Germany
[4] Univ Barcelona, Hosp Clin, Barcelona, Spain
[5] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada
[6] Hadassah Hebrew Univ Med Ctr, Jerusalem, Israel
[7] Univ Insubria, Varese, Italy
[8] Emory Univ, Sch Med, Atlanta, GA USA
[9] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[10] St Louis Hosp, AP HP, Paris, France
[11] Paris Diderot Univ, Paris, France
[12] Guys & St Thomas NHS Fdn Trust, London, England
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S786
引用
收藏
页码：320 / 321
页数：2
相关论文
共 50 条
  • [41] PACRITINIB (PAC) VS BEST AVAILABLE THERAPY (BAT), INCLUDING RUXOLITINIB, IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF) AND BASELINE THROMBOCYTOPENIA: FOCUS ON ANEMIA IN THE PHASE 3 PERSIST-2 TRIAL
    Talpaz, M.
    Mascarenhas, J.
    Hoffman, R.
    Gerds, A. T.
    Stein, B.
    Gupta, V.
    Szoke, A.
    Drummond, M.
    Pristupa, A.
    Granston, T.
    Daly, R.
    Al-Fayoumi, S.
    Callahan, J. A.
    Singer, J. W.
    Gotlib, J.
    Jamieson, C.
    Harrison, C.
    Mesa, R.
    Verstovsek, S.
    HAEMATOLOGICA, 2017, 102 : 279 - 280
  • [42] Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis
    Gowin, K.
    Kosiorek, H.
    Dueck, A.
    Mascarenhas, J.
    Hoffman, R.
    Reeder, C.
    Camoriano, J.
    Tibes, R.
    Gano, K.
    Palmer, J.
    Mesa, R.
    LEUKEMIA RESEARCH, 2017, 60 : 31 - 35
  • [43] Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3trial
    Harrison, Claire N.
    Mesa, Ruben
    Talpaz, Moshe
    Al-Ali, Haifa Kathrin
    Xicoy, Blanca
    Passamonti, Francesco
    Palandri, Francesca
    Benevolo, Giulia
    Vannucchi, Alessandro Maria
    Mediavilla, Clemence
    Iurlo, Alessandra
    Kim, Inho
    Rose, Shelonitda
    Brown, Patrick
    Hernandez, Christopher
    Wang, Jia
    Kiladjian, Jean-Jacques
    LANCET HAEMATOLOGY, 2024, 11 (10): : e729 - e740
  • [44] RESULTS FROM A 3.5-YEAR UPDATE OF COMFORT-II, A PHASE 3 STUDY COMPARING RUXOLITINIB (RUX) WITH BEST AVAILABLE THERAPY (BAT) FOR THE TREATMENT OF MYELOFIBROSIS
    Harrison, C.
    Niederwieser, D.
    Vannucchi, A.
    Kiladjian, J. J.
    Barbui, T.
    Gisslinger, H.
    Passamonti, F.
    Cervantes, F.
    Al-Ali, H. K.
    Cilloni, D.
    Zachee, P.
    Descamps, L.
    Stalbovskaya, V.
    Gopalakrishna, P.
    Knoops, L.
    Barosi, G.
    HAEMATOLOGICA, 2014, 99 : 126 - 127
  • [45] Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies
    Mesa, Ruben A.
    Talpaz, Moshe
    Kiladjian, Jean-Jacques
    Harrison, Claire N.
    Verstovsek, Srdan
    Buckley, Sarah A.
    Roman-Torres, Karisse
    Mascarenhas, John
    BLOOD, 2019, 134
  • [46] RUXOLITINIB PROVES SUPERIOR TO BEST AVAILABLE THERAPY IN A PROSPECTIVE, RANDOMIZED, PHASE 3 STUDY (RESPONSE) IN PATIENTS WITH POLYCYTHEMIA VERA RESISTANT TO OR INTOLERANT OF HYDROXYUREA
    Vannucchi, A. M.
    Kiladjian, J. J.
    Griesshammer, M.
    Masszi, T.
    Durrant, S.
    Passamonti, F.
    Harrison, C. N.
    Pane, F.
    Zachee, P.
    Mesa, R.
    He, S.
    Jones, M. M.
    Garrett, W.
    Li, J.
    Francillard, N.
    Habr, D.
    Verstovsek, S.
    HAEMATOLOGICA, 2014, 99 : 790 - 790
  • [47] Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
    C N Harrison
    A M Vannucchi
    J-J Kiladjian
    H K Al-Ali
    H Gisslinger
    L Knoops
    F Cervantes
    M M Jones
    K Sun
    M McQuitty
    V Stalbovskaya
    P Gopalakrishna
    T Barbui
    Leukemia, 2017, 31 : 775 - 775
  • [48] Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis previously treated with a JAK inhibitor (MOMENTUM): an updated analysis of an international, double-blind, randomised phase 3 study
    Gerds, Aaron T.
    Verstovsek, Srdan
    Vannucchi, Alessandro M.
    Al-Ali, Haifa Kathrin
    Lavie, David
    Kuykendall, Andrew
    Grosicki, Sebastian
    Iurlo, Alessandra
    Goh, Yeow Tee
    Lazaroiu, Mihaela C.
    Egyed, Miklos
    Fox, Maria Laura
    McLornan, Donal
    Perkins, Andrew
    Yoon, Sung-Soo
    Gupta, Vikas
    Kiladjian, Jean-Jacques
    Granacher, Nikki
    Lee, Sung-Eun
    Ocroteala, Luminita
    Passamonti, Francesco
    Harrison, Claire N.
    Oh, Stephen
    Klencke, Barbara J.
    Yu, Jing
    Donahue, Rafe
    Kawashima, Jun
    Mesa, Ruben
    LANCET HAEMATOLOGY, 2023, 10 (09): : E735 - E746
  • [49] Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
    Harrison, Claire N.
    Schaap, Nicolaas
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Jourdan, Eric
    Silver, Richard T.
    Schouten, Harry C.
    Passamonti, Francesco
    Zweegman, Sonja
    Talpaz, Moshe
    Verstovsek, Srdan
    Rose, Shelonitda
    Shen, Juan
    Berry, Tymara
    Brownstein, Carrie
    Mesa, Ruben A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (06) : 594 - 603
  • [50] Biomarker and Safety Analyses of Patients With Steroid-Refractory Acute Graft-Vs-Host Disease Treated With Ruxolitinib or Best Available Therapy in the Randomized, Phase 3 REACH2 Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (02) : 10 - 12
12345